Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial

Table 3 Summary of adverse event in the control and the hUC-MSC groups

Group	All (n = 39)	Control (n = 20)					hUC-MSC (n = 19)					P value^A
AE	Number (%)	Number (%)	Onset time post-treatment				Number (%)	Onset time post-treatment
AE	Number (%)	Number (%)	24 h	7 days	30 days	After 30 days	Number (%)	24 h	7 days	30 days	After 30 days
Upper respiratory infection	24 (61.54%)	14 (70.0%)	0	1	3	10	10 (52.6%)	0	2	2	6	0.333
Diarrhea	15 (38.46%)	9 (45.0%)	0	0	2	7	6 (31.6%)	0	0	2	4	0.514
Fever	11 (28.21%)	4 (20.0%)	0	1	1	2	7 (36.8%)	3	0	2	2	0.301
Vomiting	8 (20.51%)	3 (15.0%)	0	0	0	3	5 (26.3%)	0	0	1	4	0.451
Constipation	4 (10.26%)	3 (15.0%)	0	0	1	2	1 (5.3%)	0	0	0	1	0.605

Abbreviations: AE adverse event, hUC-MSC human umbilical cord-derived mesenchymal stem cell
^AP value was calculated by Fisher’s exact test on the incidence between groups

ISSN: 1757-6512